Novel photodynamic therapeutic treatment for acne
Oslo, Norway, January 13, 2012: Photocure ASA (OSE: PHO), a
specialty pharmaceutical company focused on photodynamic
technologies in dermatology and cancer, has completed
patient enrolment according to schedule in its Phase IIb
study using Visonac, a novel topical acne treatment.
The Phase IIb trial is a randomized, double-blind, placebo
controlled study in patients with moderate to severe acne
vulgaris. It will measure safety and efficacy in patients
aged 12 - 35 years, who will receive four treatments over a
six week period. The cream is applied to the acne area, and
after a short incubation time, the skin is illuminated with
red light. Fifteen centres in the US have recruited a total
of 150 patients to this study. The participants have been
office based dermatology practices and hospitals. The
results are anticipated in 3Q2012 and will support the
design of the pivotal Phase III studies in the US and
Europe.
Acne is the single most common skin disease worldwide, and
affects up to 85% of all 12-24 year olds. There is a high
unmet medical need for patients with moderate to severe
acne, where the current mainstay of treatment is oral
antibiotics and/or retinoids. Visonac is being developed as
the first photodynamic therapeutic option for this large
patient population, which can easily and conveniently be
administered in dermatology offices. By avoiding the risks
of increased antibiotic resistance from long term exposure,
and providing a highly tolerable alternative to
isotretinoin, Visonac has the potential to satisfy a high
unmet medical need. Clinical proof of concept has
previously been demonstrated with an excellent safety
profile and minimal patient down time.
Kjetil Hestdal, President and CEO, said: "We are delighted
to see that patient recruitment has been successfully
completed in line with our aggressive time line. This
highlights the interest from patients suffering from
moderate to severe acne, and we expect data will continue
to support the potential of Visonac as an effective
alternative treatment to current therapies."
For further information, please contact:
Photocure
President & CEO Kjetil Hestdal
Tel: + 47 913 19 535, Email: kh@photocure.no
M: Communications
Mary Clark, Amber Bielecka, Hollie Vile
Tel: +44 207920 2361, Email: photocure@mcomgroup.com
About Visonac®
The Visonac® cream is applied to the acne area, and after a
short incubation time, the skin is illuminated with red
light. The mechanism of action appears to involve killing
of bacteria as well as specific action on sebaceous glands
and inflammatory cells.
About Photocure ASA
Photocure ASA is a worldwide leader in photodynamic
technology. Listed on the Oslo Stock Exchange (OSE: PHO),
Photocure is focused on photodynamic technologies in
dermatology and cancer. The company strives to solve unmet
needs by developing new and innovative solutions based on
its patented Photocure Technology™. Photocure markets and
sells its own products in selected markets and has
developed strong partnerships with leading pharmaceutical
companies on a regional and global basis. Photocure's
bladder cancer diagnostic product, Cysview/Hexvix is
approved in Europe and the US. In addition, the company
markets Allumera®, a photodynamic cosmetic in the US.
Setting new standards for diagnosis and treatment of
several different conditions, Photocure Technology™ is
continuously being tested for new products and applications
in cancer and dermatology.
Visonac®, Allumera®, Photocure® and Cysview™/Hexvix® are
registered trademarks of Photocure ASA. For more
information about Photocure, visit .
This information is subject of the disclosure requirements
acc. to §5-12 vphl (Norwegian Securities Trading Act).
distribué par | Ce noodl a été diffusé par Photocure ASA et initialement mise en ligne sur le site http://www.photocure.com. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-13 10:46:09 AM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |